News

Agios has its first broad rare-hematology launch in hand. Following FDA approval in December, Aqvesme (mitapivat 100 mg) is...

Agios Pharmaceuticals will report fourth quarter and full-year 2025 results on February 12, 2026, via webcast. For a rare-hematology...

Beyond Air reported fiscal Q3 revenue of $2.2 million, up 105% year over year and 21% sequentially, turned a...

Medicenna has updated mid‑stage data for its beta‑selective IL‑2 superkine, MDNA11, reporting objective response rates of 36% as monotherapy...

Rezolute reported a mixed clinical and corporate update: its Phase 3 SUNRIZE trial in congenital hyperinsulinism did not meet...

Beyond Air reported fiscal Q3 results with revenue up 105% year over year to $2.2 million, maintained full-year guidance...

CRISPR Therapeutics reported fourth-quarter and full-year 2025 results, spotlighting commercial traction for CASGEVY and a pipeline tilting from ex...

Biofrontera reported positive, statistically significant Phase 3 results for Ameluz photodynamic therapy using the RhodoLED platform in mild to...

PacBio reported fourth-quarter 2025 revenue of $44.6 million, up 14% year over year and 16% sequentially, bringing full-year revenue...

Grace Therapeutics has a PDUFA date of April 23, 2026 for GTX-104, its intravenous formulation of nimodipine for aneurysmal...